-+ 0.00%
-+ 0.00%
-+ 0.00%

Astrazeneca’s BLA For Sone-Ve Accepted And Granted Priority Review In US For 2nd And Later-Line Treatment Of Patients With CLDN18.2-Positive Advanced Gastric/GEJ Cancers; PDUFA Target Date Expected During Q2 Of 2027

Benzinga·11/19/2026 12:16:13
Listen to the news

Based on CLARITY-Gastric01 Phase III trial results which showed Sone-Ve reduced the risk of death by 42% in this setting

Consistent Sone-Ve efficacy data across CLDN18.2 expression levels (>25%) supports potential use in up to 60% of patients in this setting

AstraZeneca’s Biologics License Application (BLA) for sonesitatug vedotin (Sone-Ve) has been accepted and granted Priority Review in the US for the 2nd and later-line treatment of patients with locally advanced or metastatic gastric cancer, gastroesophageal junction (GEJ) cancer or esophageal adenocarcinoma (EAC) with Claudin 18.2 (CLDN18.2) expression on at least 25% of tumor cells at any staining intensity.

The Food and Drug Administration (FDA) grants Priority Review to applications for medicines that, if approved, would offer significant improvements over available treatment options by demonstrating safety or efficacy improvements, preventing serious conditions or enhancing patient compliance.1 The Prescription Drug User Fee Act date, the FDA action date for their regulatory decision, is anticipated during the second quarter of 2027.